Introduction {#sec1}
============

Patients reliant on haemodialysis renal replacement therapy for end stage kidney disease (ESKD) are at risk of contracting SARS-CoV-2 and developing severe coronavirus disease 2019 (COVID-19). Most haemodialysis patients attend dialysis units as outpatients, often via institutional transport, and receive therapy thrice weekly in shared clinical areas. In Brescia, Italy, 15% of the chronic haemodialysis population developed COVID-19 [@bib1]. Mortality rates in dialysis patients with COVID-19 are high [@bib2]. As of May 6^th^, 197 of the 977 (20.2%) in-centre haemodialysis patients in London, UK, who contracted COVID-19 had died [@bib3]. The high prevalence of co-morbidities [@bib4] associated with COVID-19 severity, such as diabetes, age and Black, Asian or Minority ethnicity (BAME) [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], may contribute to both poor prognosis and limited access to inpatient intensive care for haemodialysis patients during the COVID-19 pandemic. However, the contributors to COVID-19 severity, including the influence of co-morbidities on clinical outcomes, have not been established in haemodialysis patients. The effects of the dialysis prescription, including ultrafiltration volume that impacts fluid balance status, on COVID-19 clinical outcomes are also not known. Outpatient dialysis attendances provide opportunity to monitor COVID-19 progression early in community-based populations who would otherwise not encounter clinical staff. Therefore, analysis of outpatient haemodialysis patients with COVID-19 may inform dialysis prescriptions and identify risk factors for future COVID-19 severity.

Imperial College Healthcare NHS Trust provides chronic renal replacement therapy for 1530 outpatients from a catchment population of about 2.5 million in North West London. The majority of patients receive in-centre outpatient haemodialysis at either the central Hammersmith hospital unit or one of eight satellite haemodialysis units. To limit SARS-CoV-2 transmission, from 9^th^ March 2020 we screened all in-centre haemodialysis patients for fever and COVID-19 symptom before each dialysis session [@bib11]. Patients with possible COVID-19 were segregated within their unit and tested for SARS-CoV-2 by nasopharyngeal swab. Patients with detectable SARS-CoV-2 received subsequent haemodialysis in isolated units ([Figure 1](#fig1){ref-type="fig"} ) until symptom improvement and for at least 14 days.Figure 1Flow chart demonstrating cohorts of patients managed on the isolated outpatient haemodialysis unit for individuals with COVID-19 (IsolHD). Following detection of SARS-CoV-2 and diagnosis of coronavirus disease 2019 (COVID-19), patients received ongoing haemodialysis in isolated clinical areas. Of 106 patients managed on IsolHD, 85 did not require hospitalisation at COVID-19 diagnosis and received the first haemodialysis session post COVID-19 diagnosis no IsolHD (IsoldHD-first cohort). The remaining 21 patients were admitted at the time of COVID-19 diagnosis and received outpatient IsolHD dialysis after clinical improvement and receiving inpatient haemodialysis. We analysed both the IsolHD-first and total IsolHD cohorts.

We have completed detailed analyses of serially recorded clinical features from all patients managed at our first isolated haemodialysis unit (IsolHD) for COVID-19 patients. We have demonstrated outpatient haemodialysis is appropriate for most patients with COVID-19, revealed important insight into the progression of COVID-19 in haemodialysis patients and identified clinical features and management strategies that associate with future hospital admission and death.

Materials and Methods {#sec2}
=====================

This was a cohort study of all COVID-19 haemodialysis patients managed on IsolHD. Data were recorded as part of routine clinical care in electronic healthy records and clinical results systems. Analysed characteristics are listed in [Table 1](#tbl1){ref-type="table"} and [Table 3](#tbl3){ref-type="table"} . Data were available from every IsolHD and inpatient dialysis session for all patients. This service analysis was approved by the renal quality and safety (governance) committee of Imperial College Healthcare NHS Trust, in view of the project being an evaluation of service change and development during the Covid-19 pandemic.Table 1Characteristics at first haemodialysis session following COVID-19 diagnosisCharacteristicAll patientsOutpatientAdmitted*P* valueSurvivedDeathP value**Number of patients, n**10656509016**Age**65 (54-74)62 (52-72)68 (58-77)0.0665 (53-72)76 (61-80)0.008^a^**Female**40 (38)20 (36)20 (40)0.731 (34)9 (56)0.2**BAME**89 (84)45 (80)44 (88)0.373 (81)16 (100)0.07**Active on transplant list**24 (23)19 (34)7 (14)0.02^b^24 (27)2 (13)0.3**Uses institutional transport**40 (38)14 (25)26 (52)0.005^c^35 (39)5 (31)0.8**Diabetes**57 (54)30 (54)27 (54)\>0.9948 (53)9 (56)\>0.99**Prescribed ACEi or ARB**37 (35)22 (39)15 (30)0.435 (39)2 (13)0.05^d^**Prescribed immunosuppression**14 (13)7 (13)7 (14)\>0.9913 (14)1 (6)0.7**Cause ESKDGenetic**9 (8)8 (14)1 (2)0.29 (10)0 (0)0.3**Autoimmune**16 (15)13 (23)3 (6)0.02^e^16 (18)0 (0)0.1**Diabetes**45 (42)18 (32)27 (54)0.03^f^34 (38)11 (69)0.01^g^**Other vascular disease**20 (19)10 (18)11 (22)0.617 (19)4 (25)0.5**Other**15 (14)7 (13)8 (16)0.814 (16)1 (6)0.5**SymptomsFever (\> 37.8 °C)**87 (82)45 (80)42 (84)0.872 (80)15 (94)0.3**Cough**49 (46)27 (48)22 (44)0.742 (47)7 (44)\>0.99**Breathlessness**31 (29)10 (18)21 (42)0.01^h^27 (30)4 (25)0.8**Myalgia**28 (26)17 (30)11 (22)0.424 (27)4 (25)\>0.99**Diarrhoea**20 (19)14 (25)6 (12)0.120 (22)0 (0)0.04^i^**Coryza**17 (16)8 (14)9 (18)0.816 (18)1 (6)0.5**Nausea**9 (11)7 (18)2 (5)0.098 (12)1 (8)\>0.99**Clinical observations pre HDSaO**~**2**~98 (96-100)99 (97-100)98 (95-100)0.03^j^99 (97-100)98 (93-100)0.05^k^**SBP (mmHg)**150 (132-165)147 (130-164)153 (134-174)0.4150 (131-164)153 (138-175)0.6**DBP (mmHg)**76 (64-88)77 (65-88)73 (62-86)0.477 (65-88)69 (61-85)0.1**Blood testsHB, g/L (NR 114-150)**109 (98-120)112 (96-122)107 (98-113)0.1109 (97-120)108 (100-116)0.9**WCC, x10**^**9**^**/L (NR 4.2-11.2)**4.8 (3.9-6.7)4.3 (3.8-6.0)5.3 (4.0-8.0)0.02^l^4.6 (3.9-6.4)5.7 (4.9-9.7)0.02^m^**Lymphocytes, x10**^**9**^**/L (NR 1.1-3.6)**1.0 (0.7-1.4)1.0 (0.7-1.5)0.9 (0.7-1.4)0.51.0 (0.7-1.4)0.9 (0.6-1.4)0.5**PLT, x10**^**9**^**/L (NR 135-400)**161 (130-228)166 (135-230)153 (130-227)0.6160 (131-229)171 (110-227)0.8**CRP, mg/L (NR \<5)**44 (13-117)29 (10-71)94 (26-164)P\<0.001^n^39 (13-100)142 (37-205)0.001^p^**ALT, unit/L (NR \<34)**14 (10-20)14 (9-19)14 (10-25)0.514 (10-21)14 (8-16)0.4**LDH, unit/L (NR 125-243)**285 (226-375)251 (221-341)324 (247-425)0.008^q^269 (226-367)341 (290-467)0.02^r^**Ferritin, μg/L (NR 20-300)**799 (502-1276)723 (434-1041)893 (589-2012)0.02^s^786 (494-1276)864 (588-1893)0.4**CK, unit/L (NR 25-200)**88 (61-184)88 (63-167)85 (57-226)0.683 (62-168)132 (52-334)0.4**Troponin, ng/L (NR \<15)**35 (22-92)29 (19-70)55 (29-137)0.02^t^33 (20-81)63 (39-207)0.006^u^**D-dimer, μg/L (NR \<500)**1499 (942-2751)1171 (674-2044)2096 (1280-3520)P\<0.001^v^1468 (799-2615)2166 (1209-3533)0.1[^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22][^23][^24][^25]Table 3Characteristics at consecutive isolated haemodialysis sessions following COVID-19 diagnosisCohortCharacteristicHD1HD2HD3P value HD1-HD2-HD3**Total**Number of patients, n857770Pre HD SaO~2~ (%)98 (97-100)98 (95-100)98 (95-100)0.2Post HD SaO~2~ (%)98 (96-100)98 (96-100)98 (95-100)0.9Any documented hypoxia (SaO~2~ \<93%)14 (16)13 (17)13 (19)0.9Pre HD SBP (mmHg)149 (133-164)147 (130-165)133 (129-164)0.8Post HD SBP (mmHg)144 (129-162)142 (130-165)147 (125-164)0.99Lowest recorded SBP (mmHg)131 (110-148)128 (113-147)133 (112-145)0.9Pre HD weight (kg)74 (66-115075 (67-113)74 (66-111)0.97Net UF (L)1.5 (1.0-2.0)1.5 (1.0-2.0)1.4 (1.0-2.0)0.6Net UF / pre HD weight (%)2.2 (1.2-2.7)2.1 (1.2-2.8)1.9 (1.2-4.7)0.6**Outpatient only**Number of patients, n56 (66)55 (71)55 (79)Pre HD SaO~2~ (%)99 (97-100)98 (96-100)98 (97-100)0.5Post HD SaO~2~ (%)98 (97-100)99 (97-100)99 (97-100)0.8Any documented hypoxia (SaO~2~ \<93%)4 (7)3 (5)6 (11)0.6Pre HD SBP (mmHg)147 (130-164)145 (123-170)152 (133-164)0.9Post HD SBP (mmHg)144 (128-161)142 (127-164)149 (132-165)0.6Lowest recorded SBP (mmHg)132 (115-149)127 (112-146)136 (116-153)0.5Pre HD weight (kg)75 (66-85)75 (66-86)74 (66-85)0.98Net UF (L)1.5 (1.0-2.0)1.5 (1.0-2.0)1.5 (1.0-2.0)0.9Net UF / pre HD weight (%)2.3 (1.3-2.7)2.2 (1.2-2.8)2.1 (1.4-2.7)0.8**Future hospital admission**Number of patients, n29 (34)22 (29)15 (21)Pre HD SaO~2~ (%)98 (94-99)96 (93-98)^a^95 (89-96)^b^0.004Post HD SaO~2~ (%)96 (94-99)^c^94 (89-96)^d^94 (91-96)^e^0.06Any documented hypoxia (SaO~2~ \<93%)10 (34)^f^10 (45)^g^7 (47)^h^0.6Pre HD SBP (mmHg)152 (136-169)149 (140-164)126 (108-150)0.09Post HD SBP (mmHg)150 (134-175)142 (132-171)131 (117-163)0.3Lowest recorded SBP (mmHg)126 (106-146)130 (115-148)116 (103-134)0.4Pre HD weight (kg)73 (67-87)72 (68-86)73 (66-85)0.98Net UF (L)1.5 (1.0-1.9)1.4 (1.0-1.9)1.0 (0.5-1.5)^i^0.3Net UF / pre HD weight (%)1.7 (1.2-2.5)1.9 (1.3-2.5)1.3 (0.8-2.1)0.4**Survived 28 days**Number of patients, n69 (81)65 (84)63 (90)Pre HD SaO~2~ (%)99 (97-100)98 (96-100)98 (96-100)0.3Post HD SaO~2~ (%)98 (97-100)99 (97-100)99 (97-100)0.9Any documented hypoxia (SaO~2~ \<93%)9 (13)7 (11)9 (15)0.8Pre HD SBP (mmHg)149 (131-163)145 (126-167)147 (129-164)\>0.99Post HD SBP (mmHg)144 (127-161)142 (128-163)149 (128-163)0.7Lowest recorded SBP (mmHg)132 (111-149)128 (112-147)135 (113-148)0.7Pre HD weight (kg)74 (65-84)75 (67-85)74 (66-85)0.9Net UF (L)2.0 (1.5-3.3)1.5 (1.0-2.0)1.5 (1.0-2.0)0.5Net UF / pre HD weight (%)2.3 (1.4-2.7)2.1 (1.3-2.8)1.9 (1.3-2.6)0.5**Death by 28 days**Number of patients, n16 (19)12 (16)7 (10)Pre HD SaO~2~ (%)98 (93-99)96 (87-98)94 (86-95)^j^0.05Post HD SaO~2~ (%)96 (93-100)94 (86-96)^k^93 (91-95)^l^0.02Any documented hypoxia (SaO~2~ \<93%)5 (31)6 (50)^m^4 (57)0.4Pre HD SBP (mmHg)153 (138-175)151 (144-166)140 (108-185)0.5Post HD SBP (mmHg)159 (135-181)143 (132-184)131 (117-174)0.3Lowest recorded SBP (mmHg)127 (100-145)128 (119-148)116 (103-134)0.6Pre HD weight (kg)69 (66-88)69 (67-88)70 (60-89)0.9Net UF (L)1.2 (0.8-1.5)1.1 (0.9-1.8)1.0 (0.5-1.5)0.6Net UF / pre HD weight (%)1.6 (1.1-2.0)1.5 (1.2-2.3)1.2 (0.8-2.8)0.6[^26][^27][^28][^29][^30][^31][^32][^33][^34][^35][^36][^37][^38][^39][^40][^41]

All patients received haemodialysis for 3 to 4 hours thrice weekly. Ultrafiltration volume was prescribed at each dialysis session based on clinical assessment including pre dialysis weight. Due to patients feeling unwell, post-dialysis weight, and consequentially inter-dialytic weight gain, was often unavailable. Peripheral oxygen saturation (SaO~2~) was measured by pulse oximeter. Hypoxia was defined as SaO~2~ less than 93% on room air. Blood tests were taken at the first dialysis session post COVID-19 diagnosis. Patients were asked about symptoms and patient experience at every dialysis session. Patient follow-up was by monitoring electronic healthy records and direct correspondence with responsible outpatient haemodialysis clinicians. Outcomes were recorded at 28 days post COVID-19 diagnosis.

Every patient was assessed by a physician once per dialysis session. Oxygen was provided to all patients with SaO2\<93%. All patients received enoxaparin 20mg as dialysis anticoagulation. Acetominophen 1g (unless weight was less than 40kg) was administered for rigors, pyrexia and symptoms of fever. Antibiotics were administered if there was clinical suspicion of superimposed bacterial infection. All staff wore personal protective equipment (PPE) allocated for aerosol generating procedures. This included fit-tested FFP3 face mask, eye shield, head cover, disposable full body gown and gloves for each clinical session and additional disposable apron and pair of gloves changed for every patient interaction. The unit was re-organised to create a separate entrance and exit for staff and patients with dedicated areas for PPE donning and doffing. Patients wore surgical face masks and were not allowed to eat or drink while in IsolHD.

We analysed cohort characteristics using two clinical outcome criteria; (1) patients who required hospital admission; (2) patients who survived 28 days from COVID-19 diagnosis. Cohort size limited our analyses to the first 3 IsolHD sessions. We used GraphPad Prism 8 for statistical analyses. Data were non-parametrically distributed. Categorical data were compared by Chi-squared or Fisher's exact test. We used Baptista-Pike method to calculate odds ratio (OR) and 95% confidence interval (CI). We compared median and interquartile range of continuous variables by Kruskall-Wallis, repeated measures ANOVA, and Mann-Whitney tests. P-values were adjusted for multiple analysis with the Bonferroni-Dunn method. We used univariate and multiple logistical regression model multivariate analyses to assess whether clinical features predicted future hospital admission or death. All statistically significant associations at univariate analysis were entered in the multivariate models. We considered P-value \<0.05 to be significant.

Results {#sec3}
=======

The first COVID-19 haemodialysis case in our catchment was identified on 13^th^ March 2020. Subsequently, 300 haemodialysis patients (19.6% haemodialysis population) developed COVID-19 over 6 weeks [@bib11]. From March 17^th^, IsolHD provided outpatient haemodialysis to 106 COVID-19 patients over 8 weeks. IsolHD received all new COVID-19 cases not requiring inpatient admission until March 30^th^, when a second unit was opened ^11^. After March 30^th^, case allocation was based on haemodialysis availability.

Compared to our total dialysis population, the IsolHD cohort was of similar age (median 65 years (interquartile range (IQR) 54-74 years) for IsolHD vs 66 years (IQR 55-75) for total population), sex ratio (38% female for IsolHD vs 42% female for total population, P=0.5) and proportion of patents with diabetes (53% for IsolHD vs 45% for total population, P=0.2). The proportion of BAME patients was higher in the IsolHD cohort than the total population (84% vs 69%, P=0.001).

Fever and cough were the two most common symptoms at HD1 ([Figure 2](#fig2){ref-type="fig"} , [Table 1](#tbl1){ref-type="table"}). In general, symptom burden improved at consecutive IsolHD sessions ([Figure 2](#fig2){ref-type="fig"}). However, relative to other symptoms, cough, breathlessness, and diarrhoea were described more frequently from haemodialysis sessions 3 to 5 post COVID-19 diagnosis ([Figure 2](#fig2){ref-type="fig"}). In addition, diarrhoea was both a presenting symptom and a symptom that developed later on in the course of the illness.Figure 2Symptom burden at consecutive isolated haemodialysis sessions post COVID-19 diagnosis. Patients were asked about symptoms at every dialysis session. The bar chart shows the percentage of patients reporting each symptom at consecutive haemodialysis (HD) sessions 1-5 post COVID-19 diagnosis. The stacked bar chart shows the relative proportion of each symptom as percentages of the total number of symptoms reported at each haemodialysis session.

The flow of patients through the unit is shown in [Figure 1](#fig1){ref-type="fig"}. Of the 85 patients who received outpatient haemodialysis on IsolHD immediately following COVID-19 diagnosis (IsolHD-first cohort, Figure 1), 29 patients (34%) were admitted after median 3 dialysis sessions (IQR 2-4) over 9 days (IQR 5-12 days). 21 of 106 patients (20%) were admitted at the time of diagnosis for median 10 days (IQR 8-13 days) and attended IsolHD following discharge. There were 16 deaths (15% of the total cohort) all of which occurred during inpatient admission.

Characteristics at the first haemodialysis session following COVID-19 diagnosis (HD1) were associated with hospital admission and death at 28 days ([Table 1](#tbl1){ref-type="table"}). The cohort who did not require hospital admission (Outpatient only), had a greater proportion of individuals active on the transplant waiting list (P=0.02) and with autoimmune disease as a cause of ESKD (P=0.02). The outpatient only cohort also had higher pre dialysis SaO~2~ (P=0.03) and lower white cell count (WCC) (P=0.02), C-reactive protein (CRP) (P\<0.001), lactate dehydrogenase (LDH) (P=0.008), ferritin (P=0.02), troponin (P=0.02) and D-dimer (P\<0.001) at HD1 ([Table 1](#tbl1){ref-type="table"}). Use of institutional transport (P=0.005), diabetes as cause of ESKD (P=0.03) and symptomatic breathlessness at HD1 (P=0.01) were more common in the cohort requiring admission ([Table 1](#tbl1){ref-type="table"}).

Death within 28 days associated with older age (P=0.008) and diabetes as cause of ESKD (P=0.01). Angiotensin-converting enzyme inhibitor (ACEi) or angiotensin 2 receptor blocker (ARB) use were more common in the cohort who survived, although the association did not reach statistical significance (P=0.05). None of the 20 patients with diarrhoea at HD1 had died at 28 days (P=0.04). We did not detect differences between patients with and without diarrhoea in demographic characteristics, antibiotic use, pre-dialysis blood pressure or post-dialysis weight loss (Supplementary table S1). Survival also associated with lower WCC (P=0.02), CRP (P=0.001), LDH (P=0.02) and troponin (P=0.006) at HD1 ([Table 1](#tbl1){ref-type="table"}). Neither BAME ethnicity nor diabetes was associated with admission or death.

Multivariate analysis demonstrated non-active transplant waiting list status (P=0.04), use of institutional transport (P=0.03), and high WCC (P=0.03) were associated with increased risk of hospital admission ([Table 2](#tbl2){ref-type="table"} ). By multivariate analysis increased age (P=0.01) was the only feature associated with risk of death at 28 days from COVID-19 diagnosis ([Table 2](#tbl2){ref-type="table"}).Table 2Univariate and multivariate analysis of associations between clinical characteristics at first haemodialysis session following COVID-19 infection and risk of hospital admission or death by 28 days. The multivariate analyses included all features demonstrating significant associations at univariate analysis.OutcomeCharacteristicUnivariate analysesMultivariate analysesOdds ratio (95% confidence interval)P valueOdds ratio (95% confidence interval)P value**Hospital admission**Active transplant waiting list status0.3 (0.13-0.85)0.020.18 (0.03-0.83)0.04Uses institutional transport3.3 (1.41-7.57)0.0054.35 (1.17-18.58)0.03Autoimmune cause ESKD0.2 (0.06-0.73)0.02NSDiabetes as cause ESKD2.5 (1.13-5.29)0.03NSBreathlessness at HD13.3 (1.41-8.33)0.01NSDifference between medians (95% confidence interval)P valuePre-dialysis SaO~2~1% (0.01-2)0.03NSIncreased white cell count1.0 x10^9^/L (0.2-1.7)0.021.45 (1.06-2.13)0.03Increased CRP65 mg/L (15-79)0.0001NSIncreased LDH73 unit/L (13-93)0.008NSIncreased ferritin170 μg/L (36-474)0.02NSIncreased troponin26 ng/L (3-33)0.02NSIncreased D-dimer925 μg/L (345-1351)0.0005NS**Death by 28 days**Age11.5 years (3-17)0.0081.10 (1.03-1.19)0.01Odds ratio (95% confidence interval)P valueDiabetes as cause ESKD4.3 (1.46-11.6)0.01NSDiarrhoea at HD10.1 (0.001-0.75)0.04NSDifference between medians (95% confidence interval)P valueIncreased white cell count1.1 x10^9^/L (0.3-2.9)0.02NSIncreased CRP103 mg/L (20-121)0.001NSIncreased LDH72 unit/L (12-122)0.02NSIncreased troponin30 ng/L (9-93)0.006NS[^42]

We next questioned whether clinical parameters at consecutive outpatient haemodialysis following COVID-19 diagnosis were associated with clinical outcomes. We analysed the IsolHD-first cohort only (n=85, [Figure1](#fig1){ref-type="fig"}). The IsolHD-first cohort was similar to the total cohort (Supplementary table S2) with the exceptions that older age and higher D-dimer at HD1 were associated with both future admission (P=0.04 for age; P=0.008 for D-dimer) and death (P=0.02 for age. P=0.01 for D-dimer), and lower pre dialysis SaO2 and less diarrhoea at HD1 were associated with admission (P=0.01 for SaO~2~; P=0.002 for diarrhoea) but not death (Supplementryl table S2).

Unlike other clinical observations, pre and post dialysis SaO~2~ decreased over the first 3 dialysis sessions in the future hospital admission and death by 28 days cohorts ([Table 3](#tbl3){ref-type="table"}). Consequently, the differences in SaO2 between clinical outcome cohorts was greatest at the third haemodialysis session (HD3) post COVID-19 diagnosis; SaO~2~ were 5% and 6% lower in the 'future admission' and 'death by 28 days' cohorts respectively ([Figure 3](#fig3){ref-type="fig"} ). Also, the proportion of patients with hypoxia was greater in the cohorts who would progress to hospitalisation and death ([Figure 3](#fig3){ref-type="fig"}E and 3F). These data are potentially confounded by progressive cohort size reduction at consecutive haemodialysis sessions. Due to clinical deterioration and requirement for inpatient care, patient removal was more common in the future hospital admission and death by 28 days cohorts. The inclusion of these severe COVID-19 cases would have exaggerated differences in hypoxia and SaO~2~ between outcome cohorts~,~ and therefore their loss is unlikely to explain the differences we detected. We did not detect significant differences in blood pressure or pre dialysis weights between outcome cohorts ([Table 3](#tbl3){ref-type="table"}). There were no significant correlations between blood pressure and SaO~2~ (data not shown).Figure 3Progression of oxygen saturations (SaO~2~) and hypoxia at consecutive haemodialysis sessions in COVID-19 patients who required future hospital admission or died. Pre (A and B) and post (C and D) dialysis peripheral SaO~2~ are shown from the first (HD1), second (HD2) and third (HD3) haemodialysis sessions post COVID-19 diagnosis and divided by the presence (Y, yes, yellow squares) or absence (N, no, blue circles) of future hospital admission or death at 28 days form COVID-19 diagnosis. n, number. 3E and 3F: Percentage of patients with hypoxia (peripheral oxygen saturations \<93%) at consecutive COVID-19 isolated haemodialysis sessions who progress to (A) future hospital admission or (B) death within 28 days.

We next interrogated fluid balance management. The mean ultrafiltration volume for HD3 was significantly less than HD1 in cohorts subsequently requiring hospital admission (P=0.03) and the reduction seemed to be progressive from HD1 to HD2 to HD3 ([Table 3](#tbl3){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"} A). We saw a similar pattern when the volume was expressed as a percentage of pre-dialysis weight (P=0.07) (Supplementary Figure S1). Similar associations were identified in the cohort who died (Supplementary Figure S2). We did not identify associations between ultrafiltration volume and age or blood pressure (data not shown).Figure 4Ultrafiltration volume and d-dimer associated with future hospital admissions and death in haemodialysis patients with COVID-19. 4A: Net dialysis ultrafiltration (UF) at the first three consecutive isolated haemodialysis sessions (HD1, HD2, HD3) and the mean volume of HD1-HD3 in patients who required future hospital admission with COVID-19. UF was not available from HD1 for one patient who required future admission. 4B: D-dimer at first dialysis post COVID-19 diagnosis and future hospital admission despite mean UF volume (Mean UF/weight) from HD1-HD3 of more than 2% pre-dialysis weight. All patients with available D-dimer results were included. N, no, blue circles. Y, yes, yellow squares. n, number.

There was significant overlap in ultrafiltration volumes between the outcome cohorts ([Figure 4](#fig4){ref-type="fig"}A and Supplementary Figures S1 and S2) and some required admission despite significant net ultrafiltration. We therefore questioned whether CRP and D-dimer, as surrogates of COVID-19 severity, were raised in these individuals. D-dimer was significantly higher in patients requiring admission despite net ultrafiltration of 2% pre-dialysis weight (P=0.004) ([Figure 4](#fig4){ref-type="fig"}B). We did not detect similar associations for CRP (Supplementary Figure S3). Mean UF did not correlate significantly with D-dimer in the total IsolHD population (data not shown).

None of our patients received antiviral medication, hydroxychloroquine or corticosteroids. Antibiotics were administered to 19 of 85 (22%) IsolHD-first patients. Antibiotic use was more common in the future hospital admission cohort (11 of 29 (58%) patients) than the outpatient only cohort (8 of 56 (14%) patients, P=0.03. OR 3.7; 95% CI 1.3-10.2). There was no association between antibiotic administration and death at 28 days. In addition to routine anticoagulation administered on dialysis, 5 patients took oral coumarin for pre-existing clinical conditions. One patient admitted at COVID-19 diagnosis had pulmonary embolus. No venous thromboemboli were detected in the IsolHD-first cohort. Acetominophen was administered to 25% of the cohort at HD1 and 26% of the cohort at HD2. Acetominophen use decreased over subsequent IsolHD sessions.

We asked patients about their haemodialysis experience at IsolHD. Despite 50% of the 78 patient survey responders feeling scared or sad when first moved to IsolHD unit, 91% were happy or very happy with their overall treatment. Physician allocation to the unit increased from 1 doctor for 1 day weekly to 3 doctors for 6 days weekly. None of the nursing or medical staff at IsolHD developed symptoms of COVID-19.

Discussion {#sec4}
==========

The risk factors associated with hospital admission and death from COVID-19 have not been established in dialysis patients ^1^. Importantly, safe and effective management protocols for COVID-19 haemodialysis patients have not been identified. Our study provides essential insight into early markers of clinical severity and effective management strategies for COVID-19 in an urban, outpatient haemodialysis cohort.

Similar to non-ESKD populations, age and frailty, as represented by non-active transplant waiting list status and dependence on institutional transport, associated with worse clinical outcomes. Given that transplant waiting list status and use of hospital-organised transport are generally easily accessible and clearly documented in patient records, we were interested whether these surrogate markers of frailty would associate with COVID-19 severity. This information may allow rapid identification of patients particularly at risk of disease severity. BAME individuals were over-represented in the COVID-19 cohort and all the patients who died were of BAME ethnicity. This supports growing evidence that BAME ethnicity independently associates with COVID-19 disease severity and demands urgent research investment [@bib10] ^,^ [@bib12].

We identified novel associations with COVID-19 severity that may be specific to haemodialysis patients and our urban, multi-ethnic patient population. Our data suggest diabetes does not significantly influence risk of death from COVID-19 and therefore should not influence access to intensive care resources. We detected a trend towards ACEi or ARB use and survival. This contradicts concerns that ACEi use may contribute to COVID-19 severity. The association of diarrhoea early in COVID-19 disease with survival was not seen in a similar dialysis population from Italy ^1^ and may be anomalous to population size. However, if seen in other populations, the possibility it represents differences in, for example, immune responses or dietary intake should be considered.

Oxygen saturations decreased progressively at consecutive dialysis sessions in cohorts who would progress to hospitalisation and death. Whether this is a modifiable observation or marker of established severe pneumonitis is unclear. Progressive decreases in ultrafiltration volume at consecutive dialysis sessions corresponded with SaO~2~ patterns. Fluid balance management of COVID-19 patients has attracted debate [@bib13] ^,^ [@bib14]. Although causality cannot be inferred, our data indicate maintained ultrafiltration volumes associate with better clinical outcomes in COVID-19 dialysis patients.

We administered standard haemodialysis anticoagulation only to 94% of patients. Despite detecting raised D-dimer in 90% patients, no VTE were detected in the IsolHD-first population. Furthermore, we observed significant overlap in D-dimer levels between outcome cohorts (Figure 4B). Our findings suggest D-dimer based anticoagulation regimens for COVID-19 should not be prescribed to dialysis patients. Raised D-dimer could indicate pulmonary endothelial dysfunction and thrombosis in a subset of patients with deteriorating COVID-19 unresponsive to fluid balance management [@bib15].

The majority of our patients recovered from COVID-19 with outpatient haemodialysis management alone (Supplementary Figure S4). Excluding SaO2, clinical observations remained stable at consecutive dialysis sessions ([Table 3](#tbl3){ref-type="table"}). Despite the use of no antiviral or immunomodulatory agents and a co-morbid, urban, multi-ethnic population, our admission (47%) and mortality (15%) rates are comparable to other published studies. A cohort of 94 haemodialysis patients from Brescia, Italy documented admission and mortality rates of 54% and 29% respectively ^1^. The UK Renal Registry Survey reported mortality rates of 22% for in-centre haemodialysis patients in London ^3^. A kidney centre that provides care to 670 haemodialysis patients in South London reported a smaller proportion of patients (11.3%) who tested positive for COVID-19 and similar rates of admission (40.8%) and death (9.2%)[@bib16]. Similar to our cohort, CXOVID-19 was more common in patients who attended haemodialysis using hospital-organised patient transport^16^. Determining whether features specific to our IsolHD regimen, that involved physician review at every dialysis session and liberal use of intradialytic acetaminophen and supplemental oxygen, contributed to our relatively high survival rate requires further research.

Unlike other clinical areas for dialysis patients with COVID-19 at our hospital trust ^11^, no IsolHD staff developed COVID-19 symptoms. National UK PPE guidelines were not followed on IsolHD; staff on IsolHD used PPE normally reserved for clinical areas with aerosol generating procedures, such as intensive care units. Our data suggests the provision of comprehensive PPE, including FFP3 masks, eye shields and full body gowns, is essential for protecting healthcare staff in clinical areas with known cases from COVID-19 transmission.

Our data are limited by the cohort nature of the study and the significant patient loss at consecutive dialysis sessions. However, our study provides a rare opportunity to analyse comprehensive, thrice weekly assessments of COVID-19 patients who, without the unavoidable need for outpatient haemodialysis, would not have interacted with clinical services, but of whom 34% progressed to hospitalisation or death (Supplementary table S2).

In conclusion, we have identified novel features at diagnosis and consecutive dialysis sessions that associate with future hospitalisation and death from COVID-19. We have demonstrated outpatient haemodialysis is safe for patients with COVID-19 and highlighted strategies that will improve patient outcomes and staff safety. These results are important for the management of dialysis patients during the COVID-19 and will inform practice in the event of subsequent waves of the disease.
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[^1]: N.R.M-T and T.T. and contributed equally to the manuscript and are joint first authors.

[^2]: A list of senior clinicians at the Imperial College Healthcare NHS Trust Renal and Transplant Centre caring for these patients and collaborating with this investigation is provided in Supplementary material.

[^3]: The Outpatient cohort did not require admission to hospital during the course of COVID19 disease and recovery. The Admitted cohort received inpatient care and haemodialysis at any point during COVID19 disease. Data are reported as n (%) for categorical variables and median (interquartile range) for continuous variables. Differences are calculated with Fisher's exact test for categorical and Mann-Whitney test for continuous variables.

[^4]: BAME, Black, Asian and Minority Ethnic groups. ACEi, angiotensin-converting enzyme inhibitor. ARB, angiotensin 2 receptor blocker. ESKD, end-stage kidney disease. SaO~2~, oxygen saturations measured by peripheral pulse oximetry. SBP, systolic blood pressure. DBP, diastolic blood pressure. HD, haemodialysis. NR, normal range. HB, haemoglobin. WCC, white cell count. Lymphocytes, lymphocyte count. PLT, platelet count. CRP, c-reactive protein. ALT, alanine aminotransferase. LDH, lactate dehydrogenase. CK, creatinine kinase.

[^5]: ^a^ Difference between medians 11.5 years (95% confidence interval (CI) 3-17 years)

[^6]: ^b^ Odds ratio (OR) for admission for active transplant waiting list status = 0.3 (95% CI 0.13-0.85)

[^7]: ^c^ OR for admission for using hospital-provided transport = 3.3 (95% CI 1.41-7.57)

[^8]: ^d^ OR for death for patients prescribed ACEi or ARB = 0.2 (95% CI 0.05-0.96)

[^9]: ^e^ OR for admission for patients with autoimmune causes of ESKD = 0.2 (95% CI 0.06-0.73)

[^10]: ^f^ OR for admission for patients with diabetes as cause of ESKD = 2.5 (95% CI 1.13-5.29)

[^11]: ^g^ OR for death for patients with diabetes as cause of ESKD = 4.3 (95% CI 1.46-11.6)

[^12]: ^h^ OR for admission for breathlessness at first dialysis post SARS-CoV2 diagnosis = 3.3 (95% CI 1.41-8.33)

[^13]: ^i^ OR for death for diarrhoea at first dialysis post SARS-CoV2 diagnosis = 0.1 (95% CI 0.001-0.75)

[^14]: ^j^ Difference between medians 1% SaO~2~ (95% CI 0.01-2)

[^15]: ^k^ Difference between medians 1% SaO~2~ (95% CI 0.01-3)

[^16]: ^l^ Difference between medians 1.0 x10^9^/L (95% CI 0.2-1.7)

[^17]: ^m^ Difference between medians 1.1 x10^9^/L (95% CI 0.3-2.9)

[^18]: ^n^ Difference between medians 65 mg/L (95% CI 15-79)

[^19]: ^p^ Difference between medians 103 mg/L (95% CI 20-121)

[^20]: ^q^ Difference between medians 73 unit/L (95% CI 13-93)

[^21]: ^r^ Difference between medians 72 unit/L (95% CI 12-122)

[^22]: ^s^ Difference between medians 170 μg/L (95% CI 36-474)

[^23]: ^t^ Difference between medians 26 ng/L (95% CI 3-33)

[^24]: ^u^ Difference between medians 30 ng/L (95% CI 9-93)

[^25]: ^v^ Difference between medians 925 μg/L (95% CI 345-1351)

[^26]: The Outpatient only cohort did not require admission to hospital during the course of COVID19 disease and recovery. The Admitted cohort received inpatient care and haemodialysis at any point during COVID19 disease. Data are reported as n (%) for categorical variables and median (interquartile range) for continuous variables. Due to progressive clinical deterioration and requirement for hospitalisation, the cohort sizes decreased at consecutive dialysis sessions, particularly in the future hospital admission and death by 28 days cohorts.

[^27]: P-value HD1-HD2-HD3 represents differences between the three HD sessions calculated with Chi-squared for categorical and repeated measures ANOVA test for continuous variables. Differences between clinical outcome cohorts were calculated with Fisher's exact test for categorical and Mann-Whitney test for continuous variables. P-values were adjusted for multiple analysis with Bonferroni-Dunn method.

[^28]: HD, haemodialysis. SaO~2~, oxygen saturations measured by peripheral pulse oximetry. SBP, systolic blood pressure. UF, ultrafiltration.

[^29]: ^a^ P\<0.001 compared with Outpatient only cohort. Difference between medians 2% (95% CI 1-4%)

[^30]: ^b^P\<0.001 compared with Outpatient only cohort. Difference between medians 3% (95% CI 3-5%)

[^31]: ^c^P=0.007 compared with Outpatient only cohort. Difference between medians 2% (95% CI 1-3%)

[^32]: ^d^P\<0.001 compared with Outpatient only cohort. Difference between medians 5% (95% CI 3-6%)

[^33]: ^e^P\<0.001 compared with Outpatient only cohort. Difference between medians 5% (95% CI 3-6%)

[^34]: ^f^P=0.01 compared with Outpatient only cohort. Odds Ratio (OR) for future hospital admission for hypoxia at HD1 = 6.8 (95% C) 1.8-21.1)

[^35]: ^g^P\<0.001 compared with Outpatient only cohort. OR for for future hospital admission for hypoxia at HD2 = 14.4 (95% CI 3.7-52.2)

[^36]: ^h^P=0.01 compared with Outpatient only cohort. OR for for future hospital admission for hypoxia at HD3 = 7.1 (95% CI 1.8-23.7)

[^37]: ^i^P=0.04 compared with Outpatient only cohort. Difference between medians 0.5L (95% CI 0.001-0.8L)

[^38]: ^j^P\<0.001 compared with Survived cohort. Difference between medians 4% (95% CI 3-11%)

[^39]: ^k^P\<0.001 compared with Survived cohort. Difference between medians 5% (95% CI 3-7%)

[^40]: ^l^ P\<0.001 compared with Survived cohort. Difference between medians 6% (95% CI 3-7%)

[^41]: ^m^P=0.01 compared with Survived cohort. OR for for death within 28 days for hypoxia at HD2 = 8.3 (95% CI 2.3-30.3)

[^42]: ESKD, end-stage kidney disease. HD1, first haemodialysis session following COIVD-19 diagnosis. SaO~2~, peripheral oxygen saturations. CRP, C-reactive protein (CRP). LDH, serum lactate dehydrogenase. NS, non-significant.
